Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 INGREZZA (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch on May 1, 2017 Total Revenue for the Fourth Quarter of 2017 was $94.5 Million and $161.6 Million for the Full-Year 2017 Elagolix PDUFA Action Date for Endometriosis in Q2 2018 and Uterine Fibroids Data from Two Phase III Studies Expected in Q1 2018 Results from Phase IIb Study of Valbenazine for Pediatric Tourette Syndrome Anticipated in Late 2018 PR Newswire SAN DIEGO, Feb. 13, 2018 SAN DIEGO , Feb. 13, 2018 /PRNewswire/ — Neurocrine Biosciences, Inc. […]